Literature DB >> 26131932

Myeloid disease: Another action of a thalidomide derivative.

Takumi Ito1, Hiroshi Handa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26131932     DOI： 10.1038/nature14628

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  12 in total

1.  Mechanism of auxin perception by the TIR1 ubiquitin ligase.

Authors:  Xu Tan; Luz Irina A Calderon-Villalobos; Michal Sharon; Changxue Zheng; Carol V Robinson; Mark Estelle; Ning Zheng
Journal:  Nature       Date:  2007-04-05       Impact factor: 49.962

Review 2.  Teratogenic effects of thalidomide: molecular mechanisms.

Authors:  Takumi Ito; Hideki Ando; Hiroshi Handa
Journal:  Cell Mol Life Sci       Date:  2011-01-05       Impact factor: 9.261

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Thalidomide mimics uridine binding to an aromatic cage in cereblon.

Authors:  Marcus D Hartmann; Iuliia Boichenko; Murray Coles; Fabio Zanini; Andrei N Lupas; Birte Hernandez Alvarez
Journal:  J Struct Biol       Date:  2014-11-04       Impact factor: 2.867

5.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

6.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

7.  Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.

Authors:  Philip P Chamberlain; Antonia Lopez-Girona; Karen Miller; Gilles Carmel; Barbra Pagarigan; Barbara Chie-Leon; Emily Rychak; Laura G Corral; Yan J Ren; Maria Wang; Mariko Riley; Silvia L Delker; Takumi Ito; Hideki Ando; Tomoyuki Mori; Yoshinori Hirano; Hiroshi Handa; Toshio Hakoshima; Thomas O Daniel; Brian E Cathers
Journal:  Nat Struct Mol Biol       Date:  2014-08-10       Impact factor: 15.369

8.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.

Authors:  Eric S Fischer; Kerstin Böhm; John R Lydeard; Haidi Yang; Michael B Stadler; Simone Cavadini; Jane Nagel; Fabrizio Serluca; Vincent Acker; Gondichatnahalli M Lingaraju; Ritesh B Tichkule; Michael Schebesta; William C Forrester; Markus Schirle; Ulrich Hassiepen; Johannes Ottl; Marc Hild; Rohan E J Beckwith; J Wade Harper; Jeremy L Jenkins; Nicolas H Thomä
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

9.  Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.

Authors:  Marcus Järås; Peter G Miller; Lisa P Chu; Rishi V Puram; Emma C Fink; Rebekka K Schneider; Fatima Al-Shahrour; Pablo Peña; L Jordan Breyfogle; Kimberly A Hartwell; Marie E McConkey; Glenn S Cowley; David E Root; Michael G Kharas; Ann Mullally; Benjamin L Ebert
Journal:  J Exp Med       Date:  2014-03-10       Impact factor: 14.307

10.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728
View more
  6 in total

1.  A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.

Authors:  Lifeng Li; Wenhua Xue; Zhibo Shen; Jie Liu; Min Hu; Zhenyong Cheng; Yuxing Wang; Yulu Chen; Hao Chang; Yingyi Liu; Bin Liu; Jie Zhao
Journal:  Mol Ther Oncolytics       Date:  2020-06-23       Impact factor: 7.200

2.  Molecular mechanisms of thalidomide and its derivatives.

Authors:  Takumi Ito; Hiroshi Handa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2020       Impact factor: 3.493

3.  L-Arginine prevents cereblon-mediated ubiquitination of glucokinase and stimulates glucose-6-phosphate production in pancreatic β-cells.

Authors:  Jaeyong Cho; Yukio Horikawa; Mayumi Enya; Jun Takeda; Yoichi Imai; Yumi Imai; Hiroshi Handa; Takeshi Imai
Journal:  Commun Biol       Date:  2020-09-08

4.  PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.

Authors:  Nobuyuki Shimizu; Tomoko Asatsuma-Okumura; Junichi Yamamoto; Yuki Yamaguchi; Hiroshi Handa; Takumi Ito
Journal:  Commun Biol       Date:  2021-11-11

5.  Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers.

Authors:  Etsuko Tokunaga; Takeshi Yamamoto; Emi Ito; Norio Shibata
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

Review 6.  Molecular Mechanisms of the Teratogenic Effects of Thalidomide.

Authors:  Tomoko Asatsuma-Okumura; Takumi Ito; Hiroshi Handa
Journal:  Pharmaceuticals (Basel)       Date:  2020-05-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.